Lytenava (bevacizumab-vikg)

Name: Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: Dosage
Published: 2026-09-28T12:24:10-04:00

Neovascular age-related macular degeneration

Manufacturer: Outlook Therapeutics
Regulatory submission: BLA approved July 2026
Launch: Anticipated before the end of 2026
Last updated: September 28, 2026

Section

Product information and disease description Product description Product information Dosing and administration

Dosage

1 evidence topic · 1 source

Recommended dose and dosing interval

“FOR OPHTHALMIC INTRAVITREAL INJECTION. LYTENAVA must only be administered by a qualified physician.” (opens the prescribing information at this quote)
“The recommended dose for LYTENAVA is 1.25 mg (0.05 mL of 25 mg/mL) administered by intravitreal injection once monthly (approximately 28 days).” (opens the prescribing information at this quote)